emamí limited

25th May, 2023

The Manager - Listing
The National Stock Exchange of India Ltd.
Exchange Plaza, Plot No. C/1, G. Block
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051
Scrip Code: EMAMILTD

The Manager - Listing BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001
Scrip Code: 531162

Dear Sirs,

Pursuant to Provision of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith copy of Presentation on Company's Performance update for the fourth quarter and year ended 31st March, 2023.

The aforesaid information is also disclosed on the website of the company www.emamiltd.in.

This is for your information and records.

Thanking you,

Yours faithfully,
For Emami Limited

| ARUN | Digitally signed by |
| :--- | :--- |
| KUMAR | ARUN KUMAR JOSHI |
| Date:2023.05. 25 |  |
| JOSHI | $15: 55: 18+05^{\prime 2} 0^{\prime}$ |

## A. K. Joshi

Company Secretary \& VP- Legal
(Encl. : As above)

## Navratna

AYURVEDIC OIL -Its 2 minute -
Magical Champigives

Relief from Headache, Tiredness \& Tension

With 9 Active Herbal Ingredients
emamí limited
Making people healthy \& beautiful, naturally

$$
\text { Q4FY23 \& FY23 Update } \underset{25^{\text {th }} \text { May } 2023}{\text { Un }}
$$

## Q4 \& FY23 Revenue Growth

| Particulars | Q4FY23 Growth [\%] |  | FY23 Growth [\%] |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Over PY | 4 year CAGR | Over PY | 4 year CAGR |
| - Domestic Business | 5\% | 5\% | 4\% | 5\% |
| - International Business | 19\% | 12\% | 20\% | 13\% |
| Consolidated Net Sales | 7\% | 7\% | 7\% | 6\% |
| - Other Operating Income | 208\% | 38\% | 27\% | 5\% |
| Total Revenues | 9\% | 7\% | 7\% | 6\% |

Volume growth of ~ 2\% in Domestic business
Dermicool and Helios Lifestyle contributed $\sim 10 \%$ to Revenues in 04 and $\sim 6 \%$ in FY23

## Increasing Salience of MT \& eCommerce

## MT contribution

eCommerce contribution



-19\% of Domestic sales driven by new age channels in FY23

## Navratna Range

- Navratna Range grew by 6\% in FY23 but declined by 3\% in Q4
- Irregular summer \& intermittent rains impacted summer offtakes
- Cool Oils
- Household Penetration* at $10.1 \%$ increased by 140 bps
- Consumed by $\mathbf{3 . 2}$ cr households*, an increase of $\mathbf{1 9 \%}$ over PY
बवरत्त तैल की
:चाद की चम्धी"



## Navratna Range



- Launched new TVC campaign " 2 Min Jaadu Ki Champi" with Salman Khan for Navratna Oil.
- Using the digital platform \& impact campaigns planned in BTL activations to complement $360^{\circ}$ campaign.

- Launched new commercial for Navratna Active Deo Talc featuring Varun Dhawan in double role
- Highlights the product's effectiveness in keeping users cool during hot weather .

- Launched campaign " Pariksha pe Charcha" highlighting Navratna Oil as a solution for students to relieve Exam stress and enhance concentration


## BTL Initiatives -

Participation in fairs \& festivals, rural vans, salon contact activities, dealer boards, digital paintings etc.


## Kesh King Range

- Kesh King Range grew by $1 \%$ each in 04 \& FY23
- Kesh King Oil
- Household Penetration* at $2.6 \%$ increased by $\mathbf{3 0}$ bps
- Consumed by $\mathbf{8 2}$ lac households*, an increase of $\mathbf{1 3 \%}$ over PY
- Introduced 30ml SKU at Rs. 49/- to drive trials



## Kesh King Range


'New Hair Growth' visual representation Strengthened in TVC featuring Shilpa Shetty


Impactful Campaign - Comparative Ad against Indulekha


Digital Launch of Kesh King Shampoo campaign featuring Ali Fazal

Continuous BTL support - Bus branding, festive branding, mela participation, digital wall paintings in rural, retail visibility etc.


## Pain Management Range

$\triangleright$ Pain Management Range corrected by 9\% in Q4FY23 and by $14 \%$ in FY23

- However, sales grew by $\mathbf{3 1 \%}$ in $\mathbf{~ 4} 4 \mathrm{FY} 23$ and by $\mathbf{2 9 \%}$ in FY23 compared to pre-pandemic period i.e. Q4FY19 \& FY19 respectively.

- Launched Zandu Fast Relief Spray in 04FY23 complementing the launch of Zandu Fast Relief Pain Relief Gel in Aug'22
- Recommended by The Indian Association of Physiotherapists and endorsed by Dr. Ali Irani (Ex-Indian Cricket Team physio)
- Launched Zandu Roll-On in flow wrap for better visibility at the chemist- placement vis-à-vis competition



## Pain Management Range



Chemist Visibility Campaign

- Driving permanent visibility with 900+ chemists in core markets
- Chemist visibility round the year with religious calendar with 14000+ chemists



## SKU Extensions

- Launched Zandu Balm 100ml in glass bottle exclusive eCommerce pack
- Larger SKUs (25ml/ 50ml/ 100ml) continued to gained traction



Brand Building for Ortho Vedic Oil on eCommerce

- Increasing visibility with Homepage Banner, Category Banner and Product Page banner across Amazon \& 1 mg


Brand building for Zandu Fast Relief

- Participation in conferences, exhibitions and marathons
- Connected with $1500+$ physios


## BoroPlus Range

- BoroPlus Range grew by $\mathbf{1 \%}$ in FY23 but declined by $\mathbf{2 5 \%}$ in 04
- BoroPlus Creams
- Household Penetration* at 20.3\%
- Consumed by $\mathbf{6 . 5} \mathbf{~ c r}$ households ${ }^{\star}$, increase of $\mathbf{2 \%}$ over PY



## BoroPlus Range



New communication (TVC \& print media) featuring Akshay Kumar showcasing multipurpose usage including usage as "night cream" to drive penetration and average consumption.



YouTube \& Instagram Influencer campaign for BoroPlus AloeVera Gel


Lucky draw campaign for BoroPlus prickly heat powder to increase trade engagement
号


## Male Grooming Range

- Male Grooming Range grew by 29\% in Q4FY23 and 3\% in FY23
- Fairness Creams
- Household Penetration* at $\mathbf{2 \%}$ increased by $\mathbf{3 0}$ bps over PY
- Consumed by 6.5 cr households*, increase of $\mathbf{2 \%}$ over PY


Launched digital campaign for Fair and Handsome with Salman Khan in Q4 reaching out to 3.3 crore consumers

## Healthcare Range

- Sales corrected by 12\% in FY23 \& 13\% in Q4FY23
- However, sales grew by 8\% \& 7\% in FY23 \& Q4FY23 respectively on a 4 year CAGR basis
- Zanducare performing well despite drop in immunity portfolio
- 11 mn unique visitors in FY 23 ; $17 \%$ higher than last year
- 14 Digital first launches on D2C portal in FY23



## International Business

- Sales grew by $\mathbf{1 9 \%}$ in 04 \& by $\mathbf{2 0 \%}$ in FY23
$\triangleright$ Strong growth despite high inflation, currency depreciations, disturbed macroeconomic conditions \& Russia Ukraine dispute
- MENA, CIS and SAARC regions performed well


## International Business Region wise sales salience



SAARC South Asian Association for Regional Cooperation (Major countries - Bangladesh, Nepal, Sri Lanka etc.)
MENA Middle East \& North Africa (Major countries - KSA, UAE, Qatar, Oman, Kuwait, Bahrain etc.)
CIS

## New launches in International Business



Navratna Gold Herbal Oil



Navratna Zaith Zaitoon Herbal Oil

Boroplus
Panthenol


Creme 21 - Petroleum Jelly


Creme 21 - Aloe Vera Gel

## Boroplus

Soft


## Q4FY23 Consolidated Financials

| Particulars | Q4FY23 | \% | Q4FY22 | \% | Growth over PY |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Net Sales | 8,166.0 | 97.7\% | 7,619.0 | 99.2\% | 7.2\% |
| Other Operating Income | 193.5 | 2.3\% | 62.9 | 0.8\% | 207.6\% |
| Revenue from Operations | 8,359.5 | 100.0\% | 7,681.9 | 100.0\% | 8.8\% |
| Materials Cost | 3,081.7 | 36.9\% | 2,876.9 | 37.5\% | 7.1\% |
| A\&P | 1,296.6 | 15.5\% | 1,494.7 | 19.5\% | -13.3\% |
| Staff Cost | 920.7 | 11.0\% | 788.5 | 10.3\% | 16.8\% |
| Admin and other expenses | 1,062.4 | 12.7\% | 882.4 | 11.5\% | 20.4\% |
| EBIDTA | 1,998.1 | 23.9\% | 1,639.4 | 21.3\% | 21.9\% |
| Other Income | 137.5 | 1.6\% | 302.9 | 3.9\% | -54.6\% |
| Interest | 13.7 | 0.2\% | 18.2 | 0.2\% | -24.7\% |
| Amortisation of acquired TM's/brands | 390.2 | 4.7\% | 604.3 | 7.9\% | -35.4\% |
| Depreciation/Amortisation of other assets | 249.5 | 3.0\% | 230.3 | 3.0\% | 8.3\% |
| PBT before Exceptional Items | 1,482.2 | 17.7\% | 1,089.5 | 14.2\% | 36.0\% |
| Share of Profit /(loss) of associate | (3.5) | 0.0\% | (59.3) | -0.8\% | 94.1\% |
| Exceptional Items |  | 0.0\% | (51.8) | -0.7\% | 100.0\% |
| PBT | 1,478.7 | 17.7\% | 978.4 | 12.7\% | 51.1\% |
| Tax | 62.5 | 0.7\% | (259.4) | -3.4\% | 124.1\% |
| PAT before MAT Credit Entitlement of earlier yrs | 1,416.2 | 16.9\% | 1,237.8 | 16.1\% | 14.4\% |
| MAT Credit Entitlement (for Earlier Years) |  | 0.0\% | $(2,303.3)$ | -30.0\% | 100.0\% |
| Profit After Tax | 1,416.2 | 16.9\% | 3,541.1 | 46.1\% | -60.0\% |
| Non controlling interest | (28.1) | -0.3\% | (18.5) | -0.2\% | -51.9\% |
| Profit for the Period | 1,444.3 | 17.3\% | 3,559.6 | 46.3\% | -59.4\% |

## FY23 Consolidated Financials

$₹$ in Million

| Particulars | FY23 | \% | FY22 | \% | Growth over PY |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Net Sales | 33,620.1 | 98.7\% | 31,527.2 | 98.9\% | 6.6\% |
| Other Operating Income | 437.2 | 1.3\% | 345.0 | 1.1\% | 26.7\% |
| Revenue from Operations | 34,057.3 | 100.0\% | 31,872.2 | 100.0\% | 6.9\% |
| Materials Cost | 12,013.6 | 35.3\% | 10,730.7 | 33.7\% | 12.0\% |
| A\&P | 5,607.0 | 16.5\% | 5,229.0 | 16.4\% | 7.2\% |
| Staff Cost | 3,677.6 | 10.8\% | 3,177.7 | 10.0\% | 15.7\% |
| Admin and other expenses | 4,131.5 | 12.1\% | 3,211.1 | 10.1\% | 28.7\% |
| EBIDTA | 8,627.6 | 25.3\% | 9,523.7 | 29.9\% | -9.4\% |
| Other Income | 689.3 | 2.0\% | 952.5 | 3.0\% | -27.6\% |
| Interest | 73.9 | 0.2\% | 50.7 | 0.2\% | 45.8\% |
| Amortisation of acquired TM's/ brands | 1,498.9 | 4.4\% | 2,405.7 | 7.5\% | -37.7\% |
| Depreciation/Amortisation of other assets | 973.6 | 2.9\% | 942.1 | 3.0\% | 3.3\% |
| PBT before Exceptional Items | 6,770.5 | 19.9\% | 7,077.7 | 22.2\% | -4.3\% |
| Share of Profit /(loss) of associate | (75.0) | -0.2\% | (145.8) | -0.5\% | 48.6\% |
| Exceptional Items |  | 0.0\% | (51.8) | -0.2\% | 100.0\% |
| PBT | 6,695.5 | 19.7\% | 6,880.1 | 21.6\% | -2.7\% |
| Tax | 421.4 | 1.2\% | 816.7 | 2.6\% | -48.4\% |
| PAT before MAT Credit Entitlement of earlier yrs | 6,274.1 | 18.4\% | 6,063.4 | 19.0\% | 3.5\% |
| MAT Credit Entitlement (for Earlier Years) |  | 0.0\% | $(2,303.3)$ | -7.2\% | 100.0\% |
| Profit After Tax | 6,274.1 | 18.4\% | 8,366.7 | 26.3\% | -25.0\% |
| Non controlling interest | (121.6) | -0.4\% | (23.2) | -0.1\% | -424.1\% |
| Profit for the Period | 6,395.7 | 18.8\% | 8,389.9 | 26.3\% | -23.8\% |

## Summarized Balance Sheet

$₹$ in Million

| SI. | Equity \& Liabilities | As at 31.03.2023 | As at 31.03.2022 | SI. | Assets | $\begin{array}{\|c\|} \hline \text { As at 31.03.2023 } \\ \hline \text { Audited } \\ \hline \end{array}$ | $\begin{array}{\|c\|} \hline \text { As at 31.03.2022 } \\ \hline \text { Audited } \\ \hline \end{array}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Audited | Audited |  |  |  |  |
|  | EQUITY |  |  | 1 | Non -Current Assets |  |  |
| (a) | Equity Share capital | 441 | 441 | (a) | Property, Plant and Equipment | 6,301 | 6,857 |
| (b) | Other Equity | 22,587 | 20,325 | (b) | Capital work-in-progress | 58 | 17 |
|  | Total Equity attributable to owners of the Parent | 23,028 | 20,766 | (c) | Investment Properties | 534 | 541 |
| (c) | Non-Controlling Interest | 100 | -23 | (d) | Other Intangible Assets | 4,752 | 5,601 |
|  | Total Equity | 23,128 | 20,743 | (e) | Goodwill on Consolidation | 682 | 242 |
|  |  |  |  | (f) | Right of Use Assets | 185 | 198 |
|  | LIABILITIES |  |  | (g) | Intangible assets under development | 6 | 14 |
| 1 | Non-Current Liabilities |  |  | (h) | Financial Assets |  |  |
| (a) | Financial Liabilities |  |  |  | (i) Investments |  |  |
|  | (i) Lease Liabilities | 90 | 99 |  | a) Investment in Associates | 109 | 561 |
|  | (ii) Other Financial Liabilities | 69 | 69 |  | b) Others | 1,691 | 2,071 |
| (b) | Provisions | 277 | 252 |  | (ii) Loans | 17 | 48 |
| (c) | Deferred Tax Liabilities (Net) | 134 | 75 |  | (iii) Other Financial Assets | 199 | 767 |
| (d) | Other Non-Current Liabilities | 161 | 179 | (i) | Deferred Tax Assets (net) | 3,637 | 2,838 |
|  |  |  |  | (j) | Other Non-Current Assets | 61 | 93 |
|  |  | 732 | 675 |  |  | 18,231 | 19,847 |
| 2 | Current liabilities |  |  |  |  |  |  |
| (a) | Financial Liabilities |  |  | 2 | Current assets |  |  |
|  | (i) Borrowings | 736 | 2,637 | (a) | Inventories | 3,280 | 3,576 |
|  | (ii) Lease Liabilities | 79 | 80 | (b) | Financial Assets |  |  |
|  | (ii) Trade Payables |  |  |  | (i) Investments | 1,134 | 395 |
|  | Total oustanding dues of Micro \& Small Enterprises | 313 | 337 |  | (ii) Trade Receivables | 4,146 | 3,209 |
|  | Total oustanding dues of creditors Other than Micro \& Small Enterpri | 3,850 | 3,750 |  | (iii) Cash \& Cash Equivalents | 468 | 276 |
|  | (iii) Other Financial Liabilities | 682 | 464 |  | (iv) Bank Balances other than (iii) above | 1,380 | 884 |
| (b) | Other Current Liabilities | 301 | 254 |  | (v) Loans | 60 | 38 |
| (c) | Provisions | 1,021 | 1,464 |  | (vi) Other Financial Assets | 713 | 457 |
| (d) | Current Tax Liabilities (Net) | 257 | 170 | (c) | Current Tax Assets (Net) | 7 | 9 |
|  |  |  |  | (d) | Other Current Assets | 1,680 | 1,884 |
|  |  | 7,239 | 9,157 |  |  | 12,868 | 10,728 |
|  | Total Equity and Liabilities | 31,098 | 30,575 |  | Total Assets | 31,098 | 30,575 |

Net Cash of ₹ 275 crore

Thank you

